 So phase three per se trial is a trial in newly diagnosed patients with myeloma or a transplant eligible and in this trial we investigated standard therapy with the same therapy to which that a tumor was added and the end point the question in fact was progression free survival but also a minimal residue of disease and complete response. So we did the trial of 700 patients in approximately 10 months and now the follow-up is 4 years and what we observe is that progression free survival at 4 years is 84% with dilatumum up and 67% without. So this is a considerable difference and we think that's important and also the hazard ratio for progressive free survival is 0.42 which means that 58% reduction of progression and that during and after the study. Now this is important also I have to add that the schedule was made more easy for the patient by succotaneous ethnicities of dilatum up compared with IV in the past and also we made the schedule 4 weeks rather than 3 weeks so the patients tolerated this treatment quite good and then during the maintenance which was dilatum up plus then the limonite we stopped dilatum up after 2 years if the patients were in CR and at least 1 year of MRD negativity and this was accomplishing 2-3rd of the patients and ongoing so this will be followed. So currently VRD is approved in Europe and many centers are using VRD or data VTD with dilatumite rather than dilatumite. I think that the results of this trial weren't approval by IMA and if so we expect that it will be the standard treatment for this group of patients in Europe Australia and I think across the world very soon because people have really been waiting for the results of this trial. So this is one of the dilatum up addition to standard therapy. I think also the concept of stopping a double agent maintenance after some time in patients that have responded well in order to reduce the treatment load to those patients for a longer time in maintenance. So that's for this trial. For all the trials I always think of the novel agents of course like the anti-BC main and anti-GPRC5D, Talkatum up, Teclisum up, Eldonatum up. Those agents are now in clinical evaluation for advanced myeloma but also these will be tested in the frontline setting and maybe we can further improve the results by adding them to our current per-series list.